Akari Therapeutics was Upgraded to a Hold Rating at Chardan Capital

By Austin Angelo

Akari Therapeutics (NASDAQ: AKTX) received a Hold rating and a $6 price target from Chardan Capital analyst Madhu Kumar yesterday. The company’s shares closed yesterday at $6.13, close to its 52-week low of $5.50.

According to TipRanks.com, Kumar is a 1-star analyst with an average return of -1.4% and a 51.4% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.

Akari Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.

Based on Akari Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $12.04 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $2.81 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which focuses in the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria, Guillain Barré syndrome, and atypical Hemolytic Uremic Syndrome. The company was founded in 2005 and is headquartered in London, the United Kingdom.